Pfizer News and Research RSS Feed - Pfizer News and Research

Study identifies FGF21 protein as potential therapeutic agent for cardiovascular diseases, type 2 diabetes

Study identifies FGF21 protein as potential therapeutic agent for cardiovascular diseases, type 2 diabetes

New research on the blood lipid-lowering protein FGF21 shows how it redistributes fatty acids by two distinct mechanisms. The discovery could lead to improved pharmaceutical treatment for type 2 diabetes and other obesity-related diseases. [More]
Halozyme closes $150 million royalty-backed debt transaction

Halozyme closes $150 million royalty-backed debt transaction

Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta. [More]
AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology. [More]
TSRI researchers develop new technique for modifying complex drug molecules

TSRI researchers develop new technique for modifying complex drug molecules

Chemists at The Scripps Research Institute have developed a versatile new technique for making modifications—especially one type of extremely difficult, but much-sought-after modification—to complex drug molecules. [More]
ACP publishes new Strategy for improving cancer patient outcomes

ACP publishes new Strategy for improving cancer patient outcomes

The Association for Cancer Physicians, which represents and supports medical oncologists in the UK, has published a new Strategy for improving cancer patient services and outcomes. [More]
Vtesse receives FDA's Breakthrough Therapy designation for VTS-270

Vtesse receives FDA's Breakthrough Therapy designation for VTS-270

Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial. [More]
New oral breast cancer drug has potential to combat other types of cancer

New oral breast cancer drug has potential to combat other types of cancer

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the Abramson Cancer Center in the University of Pennsylvania published this month in JAMA Oncology. [More]
Mylan announces launch of Linezolid Tablets, 600 mg in U.S.

Mylan announces launch of Linezolid Tablets, 600 mg in U.S.

Mylan N.V. today announced the U.S. launch of Linezolid Tablets, 600 mg, which is the generic version of Pfizer's Zyvox Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in adults and children for the treatment of certain infections caused by susceptible Gram-positive bacteria. [More]
Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune Pharmaceuticals Inc. a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific antibodies. [More]
IASLC lauds FDA approval of alectinib for lung cancer treatment

IASLC lauds FDA approval of alectinib for lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) is once again gratified to see the approval of a new second-generation lung cancer treatment that can help many patients in their battle against the disease. [More]
Study shows more patients with advanced NSCLC may benefit from pembrolizumab

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

More patients with advanced non-small-cell lung cancer (NSCLC) could benefit from pembrolizumab, says Professor Roy Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, presenting promising results from the pivotal phase 2/3 KEYNOTE-010 trial at the first ESMO Asia Congress in Singapore), in conjunction with a publication in The Lancet. [More]
Small airway-on-a-chip enables analysis of human COPD and asthma

Small airway-on-a-chip enables analysis of human COPD and asthma

A research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University leveraged its organ-on-a-chip technology to develop a model of the human small airway in which lung inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), the third leading cause of mortality worldwide, and asthma can be studied outside the human body. [More]
Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with Eli Lilly and Company to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE platform. [More]
Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer. [More]
Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore. [More]
Global Health Impact Index can measure actual impact of drugs worldwide

Global Health Impact Index can measure actual impact of drugs worldwide

Billions of dollars have been spent on developing drugs and supplying them around the world, but which companies' drugs are actually making an impact? The Global Health Impact Index, headed by Binghamton University Associate Professor Nicole Hassoun and highlighted in a new article published Friday in PLOS ONE, addresses this issue by ranking pharmaceutical companies based on their drugs' impact on global health. [More]
Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib). [More]
Sex differences in the brain may provide clues to why certain forms of autism more common in males

Sex differences in the brain may provide clues to why certain forms of autism more common in males

Many early-onset neurodevelopmental disorders, including autism spectrum disorders, are more common in males than females. The origin of this gender bias is not understood, partially due to a major gap in research on sex differences regarding how the brain typically develops. [More]
Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. [More]
X-rays not reliable for diagnosing hip osteoarthritis in majority of cases

X-rays not reliable for diagnosing hip osteoarthritis in majority of cases

In the majority of cases, hip x-rays are not reliable for diagnosing hip osteoarthritis (OA), and can delay the treatment of this debilitating disease. [More]
Advertisement
Advertisement